Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Standard Biotools Inc (LAB)
Standard Biotools Inc (LAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 197,094
  • Shares Outstanding, K 83,162
  • Annual Sales, $ 97,950 K
  • Annual Income, $ -190,100 K
  • 60-Month Beta 1.68
  • Price/Sales 1.79
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade LAB with:

Options Overview Details

View History
  • Implied Volatility 64.39% ( -36.58%)
  • Historical Volatility 49.85%
  • IV Percentile 19%
  • IV Rank 6.82%
  • IV High 618.96% on 03/06/23
  • IV Low 23.81% on 09/25/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 93
  • Volume Avg (30-Day) 145
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 8,856
  • Open Int (30-Day) 10,292

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.17
  • Number of Estimates 1
  • High Estimate -0.17
  • Low Estimate -0.17
  • Prior Year -0.21
  • Growth Rate Est. (year over year) +19.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.17 +9.14%
on 02/01/24
2.63 -10.06%
on 02/20/24
unch (unch)
since 01/26/24
3-Month
1.74 +36.60%
on 01/05/24
2.65 -10.57%
on 12/04/23
-0.08 (-3.27%)
since 11/28/23
52-Week
1.46 +62.33%
on 05/04/23
3.16 -25.00%
on 09/01/23
+0.55 (+30.22%)
since 02/28/23

Most Recent Stories

More News
Moore Kuehn Encourages APRN, FRGI, LAB, and CPRI Investors to Contact Law Firm

/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...

APRN : 12.99 (-0.08%)
FRGI : 8.49 (unch)
LAB : 2.39 (+0.84%)
CPRI : 46.29 (+0.04%)
LAB INVESTOR ALERT: Julie & Holleman LLP Announces Investigation of Proposed Merger Between Standard BioTools and SomaLogic

/PRNewswire/ -- Shareholder rights law firm Julie & Holleman LLP is investigating potential breaches of fiduciary duty relating to the proposed merger between...

LAB : 2.39 (+0.84%)
SLGC : 2.10 (-4.55%)
Standard BioTools Announces Second Quarter 2022 Financial Results and Provides Strategic Update

Second quarter revenue of $18.8 million Completed $250 million strategic cash infusion from Casdin Capital and Viking Global  Upgraded management team...

LAB : 2.39 (+0.84%)
Standard BioTools Announces Conference Call and Webcast of Second Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to...

LAB : 2.39 (+0.84%)
Standard BioTools Announces First Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to...

LAB : 2.39 (+0.84%)
Standard BioTools Announces Conference Call and Webcast of First Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to...

LAB : 2.39 (+0.84%)
Standard BioTools Launches Hyperion+ Imaging System, the New Standard in High-Plex Spatial Imaging

Capacity to Process 100-Plus Samples per Week, with 1.6x Lower Limit of Detection...

LAB : 2.39 (+0.84%)
Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.

New Trading Symbol (NASDAQ:LAB) Expected to be Effective April 6, 2022 Appoints New Management Team and Additional Board Members with Significant...

FLDM : 3.71 (-7.02%)
LAB.VN : 0.125 (unch)
LAB : 2.39 (+0.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Standard BioTools Inc. is a solution provider in health and disease using its proprietary mass cytometry and microfluidics technologies. It serves academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories. Standard BioTools Inc., formerly known as Fluidigm...

See More

Key Turning Points

3rd Resistance Point 2.50
2nd Resistance Point 2.44
1st Resistance Point 2.41
Last Price 2.39
1st Support Level 2.32
2nd Support Level 2.26
3rd Support Level 2.23

See More

52-Week High 3.16
Fibonacci 61.8% 2.51
Last Price 2.39
Fibonacci 50% 2.31
Fibonacci 38.2% 2.11
52-Week Low 1.46

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar